

July 17<sup>th</sup>, 2009

**RE: Notification of Change – New Dosage Form and DIN  
PrNIMOTOP® Tablets (nimodipine tablets) 30 mg**

Dear Doctor or Pharmacist,

As a follow-up to my letter dated May 26<sup>th</sup>, 2009, (please see attached for reference) this is to inform you that:

***“The Future Use requests for nimodipine tablets through the Special Access Programme” will end on July 20<sup>th</sup>, 2009.***

Bayer received a Notice of Compliance from Health Canada for NIMOTOP® 30 mg Tablets on May 7<sup>th</sup>, 2009. Due to discontinuation of the capsule dosage form, a submission was filed to Health Canada for registration of the new tablet formulation. The NIMOTOP® 30 mg Tablets can be substituted for the discontinued NIMOTOP® 30 mg Capsules, where the tablets have the same strength and dosing regimen.

***NIMOTOP® tablets will be available as of July 22<sup>nd</sup>, 2009 through regular commercial channels (i.e. wholesalers, CPDN etc).***

Please refer to the following table for the new information:

DIN	PRODUCT	STRENGTH & DOSAGE FORM	SIZE	INDICATIONS AND CLINICAL USE	PACKAGE PRICE
02325926	NIMOTOP® Tablets (nimodipine tablets)	30 mg Tablet	1 x 100	Useful as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial aneurysm	\$988.00

As a reminder, we kindly request that any NIMOTOP® 30 mg Capsules (DIN 02155923) be removed from your inventory and replaced by the new **NIMOTOP® 30 mg Tablets, DIN 02325926.**

The new NIMOTOP® Tablet Product Monograph is available on the Canadian Bayer HealthCare Website at [www.bayer.ca](http://www.bayer.ca).

If you have any questions or require additional information, please do not hesitate to contact me.

Yours Truly,



Mike Jurincic  
Manager, Strategic Pricing and Contract Partnerships, Corporate Affairs  
Bayer Inc.



Bayer HealthCare  
Pharmaceuticals

Bayer Inc.  
77 Belfield Road  
Toronto, Ontario M9W 1G6